Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 3/2018

18.06.2018 | Editorial

Lymphoma in ‘India’ at the Dawn of Targeted Therapies

verfasst von: Rajan Kapoor, Rajiv Kumar

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

Thomas Hodgkin, in 1832, as the ‘Inspector of the Dead and Curator of the Museum’ at the medical school of Guys hospital published a paper on “On Some Morbid Appearances of the Absorbant Glands and the Spleen”, what later on Samuel Wilks in the true spirit of peer recognition named as ‘Hodgkin’s disease’ in 1865 [1]. Hodgkin tried cascarilla, soda and iodine to treat his initial 07 patients with obvious lack of success and who went on to become the subjects of autopsy. The long journey in the management of lymphomas to the current day success story has been phenomenal. We are beginning to look at a chemotherapy and radiotherapy free treatment protocol as the cobweb of signal transduction pathways becomes clearer and we are able to unravel the ways to use the targeted therapies in various combinations to achieve the goal of ‘cure’. …
Literatur
1.
Zurück zum Zitat Bonnadonna G (2000) Historical review of Hodgkin’s disease. Br J Haematol 110:504–511CrossRef Bonnadonna G (2000) Historical review of Hodgkin’s disease. Br J Haematol 110:504–511CrossRef
2.
Zurück zum Zitat Bonnadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259CrossRef Bonnadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259CrossRef
3.
Zurück zum Zitat Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMed Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMed
4.
Zurück zum Zitat Stephens DM (2017) Brentuximab: Is it time for for a new “B” in ABVD? Blood 130:1281–128CrossRef Stephens DM (2017) Brentuximab: Is it time for for a new “B” in ABVD? Blood 130:1281–128CrossRef
5.
Zurück zum Zitat Kakroo A, Bafna A, Gogia A, Vora A, Pathak A, Korula A et al (2018) Management of Lymphomas: consensus document 2018 by an Indian Expert Group. Indian J Hematol Blood Transfus (Online First) Kakroo A, Bafna A, Gogia A, Vora A, Pathak A, Korula A et al (2018) Management of Lymphomas: consensus document 2018 by an Indian Expert Group. Indian J Hematol Blood Transfus (Online First)
Metadaten
Titel
Lymphoma in ‘India’ at the Dawn of Targeted Therapies
verfasst von
Rajan Kapoor
Rajiv Kumar
Publikationsdatum
18.06.2018
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2018
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-0973-6

Weitere Artikel der Ausgabe 3/2018

Indian Journal of Hematology and Blood Transfusion 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.